Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	1/7/2019 3:07:48 AM
	Read Replies (1) of 3557

Sanofi partnership is slowly disallowing. Good! Regn now need its own infrastructure in EU/exUS, or find another suitable marketing partner. investor.regeneron.com Interesting that Sanofi did not opt for CD20xCD3, LAG3 or GITR, but most importantly for anti-CTLA4. So, Sanofi do not share BMY enthusiasms that their CTLA4/PD1 combination is future of the IO/IO oncology, or that REGN candidate is no mach to Yervoy. I have been doing DD on regn`s anti-CTLA4 antibody, but data from patents and literature are limited and not sufficient to value appropriately. Anyway, this amendment give Regeneron freedom to operate outside box. Their Praluent/Kevzara/Dupi marketing collaboration stay, also anti-IL33 Abs development. I will have few more words on their Abs collaboration after 4Q data are out.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next